Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dexter Yan

Senior Reporter

Shanghai-based Dexter Yan is a senior writer covering Chinas surging pharma industry on the APAC Pharma news team. With a keen interest in commercial activities taking place around the clock, he is always on the lookout for opportunities to keep readers better informed of any developments in the field.

Latest From Dexter Yan

Junshi Joins China mRNA Mania Through Immorna JV

After immuno-oncology, mRNA is fast becoming a hot area in China as a flurry of biotechs from I-Mab to Kangtai partner with a little-known developer.

Deals China

Innovent Buys Into Ascentage, Opening New China Biopharma Chapter

The unprecedented deal between two public Chinese biotechs, Innovent Biologics and Ascentage Pharma, potentially provides an opening for more such mega-million dollar deals to come.

Deals China

Chinese Bioventures Grab $860m In Latest Public Listing, Financing Dash

Accelerated initial public listings, multi-million dollar deals and hot investment fund influxes fuel an already record-setting July for biotech fundraising in China.

China Financing

China Signals Further Clinical Trial Policy Tightening

The nation’s top drug regulator vows to adopt ICH’s guidelines on drug safety and efficacy, after dropping the industry a bombshell with the tightening of oncology drug clinical trials a week ago.

China Clinical Trials

China Public Payer Lowers Expectations As Record Novel Drugs Gain Approvals

Cost concerns and an increased number of potential entrants will dominate the annual adjustments to China's the national reimbursement drug list, with regulators moving to manage companies' expectations. 

China Market Access

China Reins In Cancer Drug Trials, Stressing Patient Needs and Benefits

China's drug regulatory authority is taking aim at strengthening randomized, controlled clinical trials conducted domestically for cancer drugs, leaving biotech stocks reeling from the proposed stricter requirements.

China Cancer
See All
UsernamePublicRestriction

Register